A Win For Allakos Inc.
Allakos Inc. (ALLK:NASDAQ) jumped higher at $1.34, a gain of 57%. On Tue, Oct 22, 2024, ALLK:NASDAQ touched a New 2-Week High of $1.34. The stock appeared on our News Catalysts scanner on Mon, Oct 14, 2024 at 09:57 PM in the 'INVESTOR UPDATE' category. From Tue, Oct 08, 2024, the stock recorded 60.00% Up Days and 63.64% Green Days
About Allakos Inc. (ALLK:NASDAQ)
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Top 10 Gainers:
- Ensysce Biosciences Inc. (ENSC:NASDAQ), 161.65%
- Genprex, Inc. (GNPX:NASDAQ), 137.75%
- ENDRA Life Sciences Inc. (NDRA:NASDAQ), 90.22%
- Allakos Inc. (ALLK:NASDAQ), 57.04%
- Digital Brands Group Inc. (DBGI:NASDAQ), 49.63%
- Aptevo Therapeutics Inc. (APVO:NASDAQ), 48.01%
- Armlogi Holding Corp. (BTOC:NASDAQ), 47.7%
- F45 Training Holdings Inc. (FXLV:NYSE), 40.74%
- Phunware, Inc. (PHUN:NASDAQ), 38.41%
- noco-noco Inc. (NCNC:NASDAQ), 37.39%